AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02789813 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fear reactivation
Description: Fear reactivation before exposure therapy.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel,up to 6 administration of intranasal gel.
Study NCT02789813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear reactivation
Description: Fear reactivation before exposure therapy.
Study NCT02789813 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No fear reactivation
Description: No fear reactivation before exposure therapy.
Study NCT02292914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
Study NCT02292914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
Study NCT03560518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration)
Study NCT03560518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration)
Study NCT01128621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1292263
Description: Tablet
Study NCT01128621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1292263
Description: Tablet
Study NCT01128621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1292263 matching placebo
Description: Tablet
Study NCT02789813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No fear reactivation
Description: No fear reactivation before exposure therapy.
Study NCT02397473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT01128621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Tablet
Study NCT01875198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Antegrade Modular Pancreatectomy with Splenectomy
Study NCT02397473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01875198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Antegrade Modular Pancreatectomy without splenectomy
Description: distal pancreatectomy without pancreatectomy
Study NCT02852187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGNUS MOBIS PEEK Cage
Description: Lumbar Interbody Fusion
Study NCT02852187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGNUS MOBIS II ST Cage
Description: Lumbar Interbody Fusion
Study NCT05346822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: integrated rehabilitation (the collaborative patient education)
Description: Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
Study NCT01024309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Posterior surgical approach for total hip arthroplasty
Description: Mini-Posterior surgical approach for total hip arthroplasty
Study NCT01024309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Anterior surgical approach for total hip arthroplasty
Description: Direct Anterior surgical approach for total hip arthroplasty
Study NCT02908100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
Study NCT02908100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
Study NCT03014999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (repetitive Transcranial Magnetic Stimulation)
Description: Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
Study NCT03014999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)
Description: Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
Study NCT03014999 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS (repetitive Transcranial Magnetic Stimulation)
Description: The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
Study NCT03271645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Depression
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
Study NCT03271645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Anxiety
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
Study NCT03271645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Stress
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
Study NCT03271645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face counselling
Description: Face-to-face counselling
Study NCT00796445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 2132231A
Description: IM solution, a course of 13 injections administered over 27 months
Study NCT00796445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM solution, a course of 13 injections administered over 27 months
Study NCT04367051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of Spironolactone
Description: Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
Study NCT04367051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of spironolactone
Description: Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
Study NCT04405466 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples
Study NCT04405466 — intervention group
Intervention type: PROCEDURE
Intervention: Throat swab
Description: Throat swab
Study NCT02208063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Study NCT02208063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT02208063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Study NCT02208063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic penicillin
Study NCT04024800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AE37 Peptide vaccine
Description: Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in > 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1).
Study NCT04024800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
Study NCT02208063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study NCT04036292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray
Study NCT04036292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study NCT02550678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
Study NCT02550678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU is chemotherapeutic agent used to treat various cancers.
Study NCT01474122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 3 mg
Description: Macitentan 3-mg tablet once daily
Study NCT01474122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 10 mg
Description: Macitentan 10-mg tablet once daily
Study NCT01474122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching macitentan tablet, once daily
Study NCT02522234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627 240 μg/kg
Description: F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
Study NCT02522234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627 320 μg/kg
Description: F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
Study NCT02914600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet administered orally once a day
Study NCT02914600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once a day
Study NCT04898361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFO closure
Description: Interventional closure of a patent foramen oval preceded by an electrophysiological study
Study NCT02274285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib Combined vaccine
Description: 0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
Study NCT02274285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV vaccine and Hib vaccine
Description: 0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
Study NCT02274285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib Combined vaccine
Description: 0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
Study NCT01721499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: weekly group and individual skills training to improve self control and decrease stress.
Study NCT01721499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: weekly group and individual skills training to improve self control and decrease stress.
Study NCT01721499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Study NCT05425563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming somatic pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
Study NCT05425563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vicarious Pain Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming vicarious pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
Study NCT05425563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Effort Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming cognitive effort stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
Study NCT04499729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
Study NCT04499729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual in the Rush Collaborative Care service
Study NCT01474798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA-18C3
Description: For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing > 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.
Study NCT02786030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach education training
Description: Printed copies of the patient management tool (PMT) and outreach education training
Study NCT02786030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No outreach education training
Description: Printed copies of the patient management tool (PMT) without outreach education training
Study NCT01918397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
Study NCT01918397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
Study NCT01918397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized background regimen (OBR)
Description: For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses.
Study NCT01918397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR)
Description: For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses.
Study NCT00756080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrulline
Description: 0.06 G/kg three times/day during 7 days
Study NCT00756080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
Study NCT04046211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
Study NCT03928197 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tilt Test
Description: Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
Study NCT00060359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00060359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV
Study NCT00060359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00275132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Tarceva (OSI-774, erlotinib) PO 150 mg daily
Study NCT00275132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo PO daily
Study NCT00913458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Study NCT05506228 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00875134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal prompt
Description: Patient hears a voice recording
Study NCT00875134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Stimulus
Description: Patient receives either a skin stimulus